Abstract
Gene silencing by small interfering RNA (siRNA) is a promising therapeutic approach for a wide range of disorders, including cancer. siRNAs against BCR-ABL can be a supportive or alternative measure to traditional chronic myeloid leukemia (CML) tyrosine kinase inhibitors (TKIs) therapies, especially given frequently-noted clinical TKI resistance. The main challenge for such approaches remains the development of effective RNAi systems for intracellular delivery. Cell-penetrating peptides (CPPs) are oligopeptides which have the ability to deliver various cargo molecules.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have